Investment Type: Venture Capital
Investment Stage: Series A
Portfolio 1
Mentions in press and media 16
| Date | Title | Description |
| 24.08.2026 | Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics | SEONGNAM, South Korea, Aug. 24, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego,... |
| 30.10.2017 | Kymera Therapeutics Raises $30M In Series A | Kymera Therapeutics LLC today announced a $30M Series A Financing round to advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases. The company is pioneering ... |
| 01.12.2015 | Eli Lilly’s venture arm invests in $25M round for Symic Biomedical | “We’re pretty unique in our approach to this,” Horne said. “It’s equally exciting and challenging.” The company has now raised $43 million since it was founded in 2012. The research comes out of Indiana – Purdue University researcher Dr. Al... |
| 01.12.2015 | Daily funding roundup - December 1, 2015 | AppDynamics raised $158M; Symic secured $25M; Deskbookers announced $1.6M funding Deskbookers, an online platform for booking work and meeting spaces, today announced that it has secured $1.6 million in seed funding from Point Nine Capital ... |
| 19.07.2015 | Easy pill to swallow: Aussie biotech startup raises $40 million in funding round | A biotech startup spun out of the University of Queensland has raised $40 million to help develop a drug, which may make injection-based treatments for some gastrointestinal diseases and disorders obsolete. Protagonist Therapeutics, a US in... |
| 24.06.2014 | Numerate Completes $8M Financing Round | Numerate, Inc., a San Bruno, CA-based biotechnology company, completed an $8m financing. The round was co-led by Atlas Venture and Lilly Ventures, with participation from existing investors. In conjunction with the funding, Bruce Booth, Ph.... |
| 10.01.2013 | Investors have put $15.5M behind cancer drug startup to revive shelved Hsp90 inhibitor | Here’s what we’ve learned about Esanex since May: It’s apparently a resurrection of Serenex, a North Carolina-based cancer drug company that was acquired by Pfizer in 2008 when it was in phase 1 development. Several former Serenex executive... |
| 02.05.2012 | Pharma startup led by Lilly Ventures execs raises $4.6 million | Esanex, which was formed in 2011, is apparently keeping details of its technology under wraps for now. It doesn’t have a website, and an email inquiry sent to Hall wasn’t returned. Previously, Hall co-founded cancer therapeutic company Sere... |
| 15.12.2011 | Cerulean Pharma Closes $15m Series D Financing | Cerulean Pharma Inc., a Cambridge, Massachusetts-based designer and developer of nanopharmaceuticals, has closed a $15m Series D financing. Backers include new investor, CVF, LLC, an affiliate of Henry Crown and Company of Chicago, Illinois... |
| 28.06.2011 | Nimbus Discovery Closes $24M Series A Financing | Nimbus Discovery LLC, a biopharmaceutical company that is applying advances in computer-based drug discovery to develop new medicines against important drug targets, closed a $24m Series A financing. The round was co-led by Atlas Venture, S... |
Show more